Jane Street
KLRS

Jane Street’s Kalaris Therapeutics KLRS Stock Holding History

Jane Street’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,114
Closed -$279K – 13424
2025
Q4 		$279K Buy
+33,114
New +$212K ﹤0.01% 8998
2025
Q1 		– Sell
-5,355
Closed -$51.7K – 11018
2024
Q4 		$51.7K Buy
5,355
+1,731
+48% +$26.2K ﹤0.01% 8960
2024
Q3 		$67.4K Sell
3,624
-3,899
-52% -$68.2K ﹤0.01% 9111
2024
Q2 		$125K Buy
+7,523
New +$133K ﹤0.01% 8645
2024
Q1 		– Sell
-2,771
Closed -$43.3K – 10255
2023
Q4 		$43.3K Buy
2,771
+668
+32% +$26.3K ﹤0.01% 8808
2023
Q3 		$104K Buy
+2,103
New +$143K ﹤0.01% 7934
2023
Q2 		– Sell
-686
Closed -$62.1K – 9739
2023
Q1 		$62.1K Sell
686
-308
-31% -$39.2K ﹤0.01% 8394
2022
Q4 		$117K Sell
994
-189
-16% -$32.1K ﹤0.01% 8007
2022
Q3 		$215K Sell
1,183
-167
-12% -$26K ﹤0.01% 8061
2022
Q2 		$121K Buy
1,350
+904
+203% +$94.8K ﹤0.01% 8532
2022
Q1 		$69K Buy
+446
New +$89K ﹤0.01% 9589
2021
Q3 		– Sell
-825
Closed -$375K – 10901
2021
Q2 		$375K Buy
+825
New +$426K ﹤0.01% 7783
2020
Q4 		– Sell
-492
Closed -$311K – 8236
2020
Q3 		$311K Buy
+492
New +$336K ﹤0.01% 5831

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Jane Street's KLRS Position: Q1 2026 in Review

Jane Street sold out of Kalaris Therapeutics (KLRS) in Q1 2026, closing a stake of 33,114 shares — an estimated $279K sold.

Jane Street first reported a position in KLRS in Q3 2020 and held it in 13 quarters. The position peaked at $375K in Q2 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Jane Street reported no remaining Kalaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 33,114 Kalaris Therapeutics shares in Q1 2026, an estimated $279K.
  • Jane Street first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 13 quarters.
  • Jane Street's Kalaris Therapeutics position peaked at $375K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.